Myeloid dendritic cells in HIV-1 infection

Current Opinion in HIV and AIDS

Volumn 6, Issue 5, 2011, Pages 379-384

  Derby, Nina ^a   Martinelli, Elena ^a   Robbiani, Melissa ^a  

^a POPULATION COUNCIL   (United States)

Author keywords

dysfunction; HIV 1; immunity; myeloid dendritic cell; pattern recognition receptors

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

CELL FUNCTION; CELL TYPE; CELLULAR IMMUNITY; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE EVASION; IMMUNOMODULATION; IMMUNOSTIMULATION; MOLECULAR MECHANICS; MOLECULAR RECOGNITION; MOLECULARLY TARGETED THERAPY; MYELOID DENDRITIC CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS CELL INTERACTION; VIRUS REPLICATION; VIRUS TRANSMISSION;

DENDRITIC CELLS; HIV INFECTIONS; HIV-1; HUMANS;

EID: 80051783673     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283499d63     Document Type: Review

References (67)

1. Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat Rev Immunol 2008; 8:447-457. (Pubitemid 351735878)
2. Wu L, KewalRamani VN. Dendritic-cell interactions with HIV: infection and viral dissemination. Nat Rev Immunol 2006; 6:859-868. (Pubitemid 44631654)
3. Cunningham AL, Donaghy H, Harman AN, et al. Manipulation of dendritic cell function by viruses. Curr Opin Microbiol 2010; 13:524-529.
4. Altfeld M, Fadda L, Frleta D, Bhardwaj N. DCs and NK cells: critical effectors in the immune response to HIV-1. Nat Rev Immunol 2011; 11:176-186.
5. Barratt-Boyes SM, Brown KN, Melhem N, et al. Understanding and exploiting dendritic cells in human immunodeficiency virus infection using the nonhuman primate model. Immunol Res 2006; 36:265-274. (Pubitemid 46402782)
6. Benlahrech A, Gotch F, Kelleher P, Patterson S. Loss of NK stimulatory capacity by plasmacytoid and monocyte-derived DC but not myeloid DC in HIV-1 infected patients. PLoS One 2011; 6:e17525.
7. Wijewardana V, Soloff AC, Liu X, et al. Early myeloid dendritic cell dysregulation is predictive of disease progression in simian immunodeficiency virus infection. PLoS Pathog 2010; 6:e1001235.
8. Dillon SM, Friedlander LJ, Rogers LM, et al. Blood myeloid dendritic cells from HIV-1-infected individuals display a proapoptotic profile characterized by decreased Bcl-2 levels and by caspase-3+ frequencies that are associated with levels of plasma viremia and T cell activation in an exploratory study. J Virol 2011; 85:397-409.
9. Centlivre M, Legrand N, Steingrover R, et al. Altered dynamics and differential infection profiles of lymphoid and myeloid cell subsets during acute and chronic HIV-1 infection. J Leukoc Biol 2011; 89:85-95.
10. Schlaepfer E, Speck RF. TLR8 activates HIV from latently infected cells of myeloid-monocytic origin directly via the MAPK pathway and from latently infected CD4+ T cells indirectly via TNF-α. J Immunol 2011; 186:4314-4324.
11. Sabado RL, O'Brien M, Subedi A, et al. Evidence of dysregulation of dendritic cells in primary HIV infection. Blood 2010; 116:3839-3852.
12. Xu H, Wang X, Pahar B, et al. Increased B7-H1 expression on dendritic cells correlates with programmed death 1 expression on T cells in simian immunodeficiency virus-infected macaques and may contribute to T cell dysfunction and disease progression. J Immunol 2010; 185:7340-7348.
13. Che KF, Sabado RL, Shankar EM, et al. HIV-1 impairs in vitro priming of naive T cells and gives rise to contact-dependent suppressor T cells. Eur J Immunol 2010; 40:2248-2258.
14. Buisson S, Benlahrech A, Gazzard B, et al. Monocyte-derived dendritic cells from HIV type 1-infected individuals show reduced ability to stimulate T cells and have altered production of interleukin (IL)-12 and IL-10. J Infect Dis 2009; 199:1862-1871.
15. Yonkers NL, Milkovich KA, Rodriguez B, et al. Accessory cell dependent NK cell mediated PBMC IFN-gamma production is defective in HIV infection. Clin Immunol 2009; 131:288-297.
16. Giardino Torchia ML, Ciaglia E, Masci AM, et al. Dendritic cells/natural killer cross-talk: a novel target for human immunodeficiency virus type-1 protease inhibitors. PLoS One 2010; 5:e11052.
17. Fontaine J, Chagnon-Choquet J, Valcke HS, et al. High expression levels of B lymphocyte stimulator (BLyS) by dendritic cells correlate with HIV-related Bcell disease progression in humans. Blood 2011; 117:145-155.
18. De Jong MA, de Witte L, Taylor ME, Geijtenbeek TB. Herpes simplex virus type 2 enhances HIV-1 susceptibility by affecting Langerhans cell function. J Immunol 2010; 185:1633-1641.
19. Martinelli E, Tharinger H, Frank I, et al. HSV-2 infection of dendritic cells amplifies a highly susceptible HIV-1 cell target. PLoS Pathog 2011.
20. Ward H, Ronn M. Contribution of sexually transmitted infections to the sexual transmission of HIV. Curr Opin HIV AIDS 2010; 5:305-310.
21. Zhu J, Hladik F, Woodward A, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009; 15:886-892.
22. Nawaz F, Cicala C, Van Ryk D, et al. The genotype of early-transmitting HIV gp120s promotes alpha4beta7-reactivity, revealing alpha(4)beta(7)/CD4 T cells as key targets in mucosal transmission. PLoS Pathog 2011; 7:e1001301.
23. Ansari AA, Reimann KA, Mayne AE, et al. Blocking of alpha4beta7 gut-homing integrin during acute infection leads to decreased plasma and gastrointestinal tissue viral loads in simian immunodeficiency virus-infected rhesus macaques. J Immunol 2011; 186:1044-1059.
24. Cavaleiro R, Baptista AP, Soares RS, et al. Major depletion of plasmacytoid dendritic cells in HIV-2 infection, an attenuated form of HIV disease. PLoS Pathog 2009; 5:e1000667.
25. Duvall MG, Lore K, Blaak H, et al. Dendritic cells are less susceptible to human immunodeficiency virus type 2 (HIV-2) infection than to HIV-1 infection. J Virol 2007; 81:13486-13498. (Pubitemid 350247843)
26. Arhel N, Lehmann M, Clauss K, et al. The inability to disrupt the immunological synapse between infected human T cells and APCs distinguishes HIV-1 from most other primate lentiviruses. J Clin Invest 2009; 119:2965-2975.
27. Quaranta MG, Mattioli B, Giordani L, Viora M. Immunoregulatory effects of HIV-1 Nef protein. Biofactors 2009; 35:169-174.
28. Cavaleiro R, Baptista AP, Foxall RB, et al. Dendritic cell differentiation and maturation in the presence of HIV type 2 envelope. AIDS Res Hum Retroviruses 2009; 25:425-431.
29. Martinelli E, Cicala C, Van Ryk D, et al. HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells. Proc Natl Acad Sci USA 2007; 104:3396-3401. (Pubitemid 46364170)
30. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11:373-384.
31. Tremblay MJ. HIV-1 and pattern-recognition receptors: a marriage of convenience. Nat Immunol 2010; 11:363-365.
32. Stax MJ, Naarding MA, Tanck MW, et al. Binding of human milk to pathogen receptor DC-SIGN varies with bile salt-stimulated lipase (BSSL) gene polymorphism. PLoS One 2011; 6:e17316.
33. Stax MJ, van Montfort T, Sprenger RR, et al. Mucin 6 in seminal plasma binds DC-SIGN and potently blocks dendritic cell mediated transfer of HIV-1 to CD4(+) T-lymphocytes. Virology 2009; 391:203-211.
34. Gringhuis SI, van der Vlist M, van den Berg LM, et al. HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat Immunol 2010; 11:419-426.
35. Harman AN, Wilkinson J, Bye CR, et al. HIV induces maturation of monocytederiveddendriticcellsandLangerhanscells. JImmunol2006;177:7103-7113. (Pubitemid 44715078)
36. Bordon Y. Dendritic cells: an inner eye for HIV. Nat Rev Immunol 2010; 10:678.
37. Harman AN, Lai J, Turville S, et al. HIV infection of dendritic cells subverts the interferon induction pathway via IRF1 and inhibits type 1 interferon production. Blood 2011; in press.
38. Harman AN, Kraus M, Bye CR, et al. HIV-1-infected dendritic cells show 2 phases of gene expression changes, with lysosomal enzyme activity decreased during the second phase. Blood 2009; 114:85-94.
39. Manel N, Hogstad B, Wang Y, et al. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature 2010; 467:214-217.
40. Laguette N, Sobhian B, Casartelli N, et al. SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011; in press.
41. Sunseri N, O'Brien M, Bhardwaj N, Landau NR. HIV-1 modified to package SIV Vpx efficiently infects macrophages and dendritic cells. J Virol 2011; 85:6263-6274.
42. Lepelley A, Louis S, Sourisseau M, et al. Innate sensing of HIV-infected cells. PLoS Pathog 2011; 7:e1001284.
43. Albin JS, Harris RS. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med 2010; 12:e4.
44. Sui Y, Zhu Q, Gagnon S, et al. Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc Natl Acad Sci USA 2010; 107:9843-9848.
45. Trapp S, Derby NR, Singer R, et al. Double-stranded RNA analog poly(I:C) inhibits human immunodeficiency virus amplification in dendritic cells via type I interferon-mediated activation of APOBEC3G. J Virol 2009; 83:884-895.
46. Thielen BK, McNevin JP, McElrath MJ, et al. Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J Biol Chem 2010; 285:27753-27766.
47. Brichacek B, Vanpouille C, Kiselyeva Y, et al. Contrasting roles for TLR ligands in HIV-1 pathogenesis. PLoS One 2010; 5.
48. Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010; 33:464-478.
49. Wong JP, Christopher ME, Viswanathan S, et al. Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine 2009; 27:3481-3483.
50. Tewari K, Flynn BJ, Boscardin SB, et al. Poly(I:C) is an effective adjuvant for antibody and multifunctional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and alphaDEC-CSP in non human primates. Vaccine 2010; 28:7256-7266.
51. Vagenas P, Aravantinou M, Williams VG, et al. A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation. PLoS One 2010; 5:e12891.
52. Vagenas P, Williams VG, Piatak M Jr, et al. Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239. J Acquir Immune Defic Syndr 2009; 52:433-442.
53. Idoyaga J, Lubkin A, Fiorese C, et al. Comparable T helper 1 (Th1) and CD8 Tcell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc Natl Acad Sci USA 2011; 108:2384-2389.
54. Klechevsky E, Flamar AL, Cao Y, et al. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood 2010; 116:1685-1697.
55. Nchinda G, Amadu D, Trumpfheller C, et al. Dendritic cell targeted HIV gag protein vaccine provides help to a DNA vaccine including mobilization of protective CD8+ T cells. Proc Natl Acad Sci USA 2010; 107:4281-4286.
56. Bozzacco L, Trumpfheller C, Huang Y, et al. HIV gag protein is efficiently cross-presented when targeted with an antibody towards the DEC-205 receptor in Flt3 ligand-mobilized murine DC. Eur J Immunol 2010; 40:36-46.
57. Reeves RK, Wei Q, Stallworth J, Fultz PN. Systemic dendritic cell mobilization associated with administration of FLT3 ligand to SIV-and SHIV-infected macaques. AIDS Res Hum Retroviruses 2009; 25:1313-1328.
58. Zhang R, Zhang S, Li M, et al. Incorporation of CD40 ligand into SHIV viruslike particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV. Vaccine 2010; 28:5114-5127.
59. Cheong C, Choi JH, Vitale L, et al. Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human antihuman DEC205 monoclonal antibody. Blood 2010; 116:3828-3838.
60. McEnery R. Vaccine candidate targeting dendritic cells enters clinical trial. IAVI Rep 2010; 14:23.
61. Taylor PR, Koski GK, Paustian CC, et al. J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells. Vaccine 2010; 28:5533-5542.
62. Taylor PR, Paustian CC, Koski GK, et al. Maturation of dendritic cell precursors into IL12-producing DCs by J-LEAPS immunogens. Cell Immunol 2010; 262:1-5.
63. Van Gulck E, Van Tendeloo VF, Berneman ZN, Vanham G. Role of dendritic cells in HIV-immunotherapy. Curr HIV Res 2010; 8:310-322.
64. Niu L, Termini JM, Kanagavelu SK, et al. Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes. Vaccine 2011; 29:2110-2119.
65. Routy JP, Boulassel MR, Yassine-Diab B, et al. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol 2010; 134:140-147.
66. Colleton BA, Huang XL, Melhem NM, et al. Primary human immunodeficiency virus type 1-specific CD8+ T-cell responses induced by myeloid dendritic cells. J Virol 2009; 83:6288-6299.
67. Hong B, Song XT, Rollins L, et al. Mucosal and systemic anti-HIV immunity controlled by A20 in mouse dendritic cells. J Clin Invest 2011; 121:739-751.